tiprankstipranks
Trending News
More News >
Stayble Therapeutics AB (SE:STABL)
:STABL

Stayble Therapeutics AB (STABL) AI Stock Analysis

Compare
0 Followers

Top Page

SE

Stayble Therapeutics AB

(Frankfurt:STABL)

Rating:34Underperform
Price Target:
Stayble Therapeutics AB's overall stock score is heavily influenced by its weak financial performance, characterized by consistent net losses and negative cash flow. Technical analysis indicates a bearish trend, while valuation metrics reflect the financial struggles typical of early-stage biotechnology firms. The stock lacks positive catalysts such as earnings calls or corporate events, further weighing down its overall score.

Stayble Therapeutics AB (STABL) vs. iShares MSCI Sweden ETF (EWD)

Stayble Therapeutics AB Business Overview & Revenue Model

Company DescriptionStayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.
How the Company Makes MoneyStayble Therapeutics AB generates revenue through the development and eventual commercialization of its proprietary treatment solutions for degenerative disc disease. The company primarily invests in clinical trials and research to bring its products to market, aiming to license its technologies to larger pharmaceutical companies upon successful trial results. Significant revenue streams are expected to arise from licensing agreements, milestone payments, and royalties from sales of approved therapies. Partnerships with research institutions and healthcare organizations may also contribute to its earnings by bolstering research capabilities and expanding market reach.

Stayble Therapeutics AB Financial Statement Overview

Summary
Stayble Therapeutics AB faces considerable financial challenges, primarily due to its inability to generate revenue while incurring high operating costs, leading to consistent net losses. The balance sheet shows financial solidity with no debt, but profitability metrics are weak. Overall, the company needs to improve its revenue generation and cost management to achieve financial sustainability.
Income Statement
12
Very Negative
Stayble Therapeutics AB has struggled to generate revenue, with a TTM revenue of $10,000, a significant increase from $0 in previous years. However, the company posts a substantial net loss of $12.4 million and negative EBIT and EBITDA margins, indicative of high operating expenses and limited revenue generation capacity within the biotechnology industry.
Balance Sheet
35
Negative
The balance sheet shows a strong equity base with a debt-to-equity ratio of 0, as the company has no debt. However, the equity ratio is 74.27%, reflecting financial stability. The company's ROE is negative, driven by significant net losses, which is concerning in terms of generating shareholder value.
Cash Flow
20
Very Negative
The company's cash flow statement indicates significant negative operating cash flow of $14.7 million TTM. Free cash flow is also negative, reflecting cash outflows that are not being offset by operating income. The operating cash flow to net income ratio is unfavorably negative, highlighting cash consumption without corresponding revenue generation.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
0.000.000.000.000.00
Gross Profit
-13.03M0.000.000.000.00
EBIT
-13.03M-23.95M-24.80M-12.14M-14.93M
EBITDA
-12.37M309.41K0.000.000.00
Net Income Common Stockholders
-12.42M-23.74M-24.23M-12.04M-16.05M
Balance SheetCash, Cash Equivalents and Short-Term Investments
2.19M14.08M12.85M37.47M10.87M
Total Assets
9.26M21.70M19.15M43.64M18.00M
Total Debt
0.00850.00K850.00K850.00K850.00K
Net Debt
-2.19M-13.23M-12.00M-36.62M-10.02M
Total Liabilities
2.38M5.19M3.87M3.83M2.45M
Stockholders Equity
6.87M16.51M15.28M39.81M15.55M
Cash FlowFree Cash Flow
-14.67M-23.54M-24.89M-9.63M-23.98M
Operating Cash Flow
-14.67M-23.54M-24.89M-9.63M-23.98M
Investing Cash Flow
0.000.001.00K-1.00K0.00
Financing Cash Flow
2.78M24.96M0.0036.15M31.19M

Stayble Therapeutics AB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.42
Price Trends
50DMA
0.46
Negative
100DMA
0.45
Negative
200DMA
0.54
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
44.97
Neutral
STOCH
16.26
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:STABL, the sentiment is Negative. The current price of 0.42 is below the 20-day moving average (MA) of 0.44, below the 50-day MA of 0.46, and below the 200-day MA of 0.54, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.97 is Neutral, neither overbought nor oversold. The STOCH value of 16.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:STABL.

Stayble Therapeutics AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.38B3.40-45.06%3.28%16.75%-0.02%
52
Neutral
kr47.32M-47.01%-94.12%-25.83%
37
Underperform
kr5.46M-107.11%94.98%
34
Underperform
kr26.26M-105.54%63.82%
32
Underperform
kr11.05M-209.54%97.86%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:STABL
Stayble Therapeutics AB
0.42
0.11
35.81%
SE:COMBI
CombiGene AB
2.47
-0.55
-18.21%
SE:LIDDS
LIDDS AB
0.05
-0.09
-66.20%
SE:QUIA
QuiaPEG Pharmaceuticals Holding AB
0.01
-0.06
-85.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.